Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany: Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)
نویسندگان
چکیده
منابع مشابه
Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients
Binding of programmed death-1 (PD-1) with its ligands (PD-L1/2) transmits a co-inhibitory signal in activated T-cells that promotes T-cell exhaustion, leading to tumor immune evasion. The efficacy of antibodies targeting PD-1 and PD-L1 has led to a paradigm shift in lung cancer treatment but the prognostic and predictive value of tumor PD-L1 expression remains controversial. Evaluating PD-1, PD...
متن کاملPD-L1 and c-MET expression and survival in patients with small cell lung cancer
BACKGROUND Blocking the binding between the PD-1 and PD-L1 has been reported to produce antitumor responses. The MET/HGF axis appears to be another signaling pathway frequently altered in small cell lung cancer (SCLC). Our study was aimed to investigate the expression and prognostic roles of PD-L1 and c-MET in SCLC. METHODS The expression levels of PD-L1 and c-MET were evaluated by immunohist...
متن کاملPD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)
In order to explore the potential patient population who could benefit from anti PD-1/PD-L1 mono or combination therapies, this study aimed to profile a panel of immunotherapy related biomarkers (PD-1, PD-L1, CTLA-4 and CD8) and targeted therapy biomarkers (EGFR, KRAS, ALK, ROS1 and MET) in NSCLC.Tumor samples from 297 NSCLC patients, including 156 adenocarcinomas (AD) and 129 squamous cell car...
متن کاملPD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability
Immunotherapy with checkpoint inhibitors, allowing recovery of effector cells function, has demonstrated to be highly effective in many tumor types and represents a true revolution in oncology. Recently, the anti-PD1 agent pembrolizumab was granted FDA approval for the first line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors show PD-L1 expression in ≥ 50% o...
متن کاملAssociation of PD-L1 expression with clinicopathologic features and overall survival in patients with non-small-cell lung cancer
Multiple lines ofevidence showed that non-small cell lung cancer (NSCLC) patients had improved clinical outcomes when immune checkpoint was blocked. Programmed death receptor 1 (PD-L1) is one of the most extensively studied molecules that are highly implicated in the response to immunotherapy in NSCLC. However, studies that report the prevalence of PD-L1 expression in NSCLC and address their as...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2019
ISSN: 0923-7534
DOI: 10.1093/annonc/mdz260.041